Third Quarter 2026
Filed Nov 3, 2026Spyre Therapeutics Reports Third Quarter 2026 Financial Results and Provides Corporate Update
The company reported completed proof-of-concept across its three IBD monotherapies and accelerated enrollment in SKYLINE Part B, while discontinuing SPY072 development in rheumatic diseases after PsA and axSpA sub-studies did not meet primary endpoints. Cash resources were strengthened by the October financing, but quarterly R&D expense and net loss increased year over year.
Key metrics
shortened, hover for the filing’s print| Metric | Value | q/q | y/y |
|---|---|---|---|
| Research and development expenses, three months ended September 30, 2026GAAP | $89.2M | – | – |
| General and administrative expenses, three months ended September 30, 2026GAAP | $16.6M | – | – |
| Total operating expenses, three months ended September 30, 2026GAAP | $105.7M | – | – |
| Loss from operations, three months ended September 30, 2026GAAP | −$105.7M | – | – |
| Interest income, three months ended September 30, 2026GAAP | $10.63M | – | – |
| Other income, three months ended September 30, 2026GAAP | $9.6M | – | – |
| Net loss, three months ended September 30, 2026GAAP | $96.1M | – | – |
| Net loss per share, basic and diluted, common, three months ended September 30, 2026GAAP | $(0.94) | – | – |
| Net loss per share, basic and diluted, Series A Preferred Stock, three months ended September 30, 2026GAAP | $(37.60) | – | – |
| Weighted-average common stock outstanding, basic and diluted, three months ended September 30, 2026GAAP | 88,410,821 | – | – |
| Research and development expenses, nine months ended September 30, 2026GAAP | $215.1M | – | – |
| General and administrative expenses, nine months ended September 30, 2026GAAP | $47.92M | – | – |
| Gain on sale of in-process research and development asset, nine months ended September 30, 2026GAAP | −$70M | – | – |
| Total operating expenses, nine months ended September 30, 2026GAAP | $193.0M | – | – |
| Loss from operations, nine months ended September 30, 2026GAAP | −$193.0M | – | – |
| Total other income (expense), nine months ended September 30, 2026GAAP | −$8.33M | – | – |
| Net loss, nine months ended September 30, 2026GAAP | −$201.3M | – | – |
| Net loss per share, basic and diluted, common, nine months ended September 30, 2026GAAP | $(2.04) | – | – |
| Cash and cash equivalents, September 30, 2026GAAP | $82.73M | – | – |
| Marketable securities, September 30, 2026GAAP | $989.2M | – | – |
| Total assets, September 30, 2026GAAP | $1.10B | – | – |
| Total liabilities, September 30, 2026GAAP | $48.19M | – | – |
| Total stockholders' equity, September 30, 2026GAAP | $1.05B | – | – |
Amounts quoted below without a unit are in thousands, as in the filing’s tables. Per-share figures are as printed.
Second half of 2029 and clinical milestones in 2027 and 2028 outlook
- NoteExpected runway into the second half of 2029
- NoteSKYLINE Part B induction data expected in the third quarter of 2027
- NoteSKYLIGHT topline Week 16 results planned in late 2027 or early 2028
- NoteThe Company plans to advance a potential best-in-class anti-TL1A monotherapy agent into pivotal studies for HS in 2027
What drove it
- R&D expense increased primarily due to higher manufacturing costs and clinical trial expenses.
- G&A expense increased primarily due to increased headcount and professional services fees.
- The change in other income was primarily due to changes in the fair value of the contingent value right liability in the prior period.
- SKYLINE Part B is enrolling ahead of schedule, enabling an increased enrollment target.
- SPY001, SPY002, and SPY003 each achieved their respective primary endpoints in SKYLINE Part A and were well tolerated with a safety profile consistent with in-class comparators.
- The company initiated the SKYLIGHT Phase 2 trial of SPY072 in HS in September 2026.
Concerns
- SPY072 will not be advanced in rheumatic disease after the PsA and axSpA SKYWAY sub-studies did not meet their primary endpoints.
- Although SPY072 demonstrated clinical activity in RA, the results did not meet the company's internal bar to prioritize advancement in RA.
- Net loss totaled $96.1 million for the third quarter of 2026, compared with $11.2 million for the third quarter of 2025.
- R&D expenses totaled $89.2 million for the third quarter of 2026, compared with $45.2 million for the third quarter of 2025.
- SKYLINE combination induction data are not expected until the third quarter of 2027.
What to watch
- Topline induction results from SKYLINE Part B for the SPY120, SPY130, and SPY230 combinations, expected in the third quarter of 2027.
- Execution against the increased SKYLINE Part B enrollment target.
- SKYLIGHT Phase 2 topline Week 16 results, planned in late 2027 or early 2028.
- Planned advancement of SPY072 into pivotal HS monotherapy studies in 2027.
- Cash runway expected into the second half of 2029.
Balance sheet and cash flow
- Cash, cash equivalents, and marketable securities of $1,071.9 million as of September 30, 2026.
- Pro forma cash of $1,467.9 million as of September 30, 2026.
- Net cash used in operating activities was $77.5 million for the third quarter of 2026.
- $378.0 million in net proceeds from the recently closed October 2026 underwritten public offering of common stock.
- $18.0 million in October 2026 at-the-market (ATM) sales.
- Total current liabilities were $40,143 (in thousands) as of September 30, 2026.
- Non-current CVR liability was $6,760 (in thousands) as of September 30, 2026. No debt was reported in the balance sheet provided.
Analysis
Spyre reported a clinical and financing update alongside third-quarter results. The principal positive development was completion of proof-of-concept for all three IBD monotherapies after positive SPY003 induction data from SKYLINE Part A. The company stated that SPY001, SPY002, and SPY003 each achieved their respective primary endpoints and were well tolerated. SKYLINE Part B, which is evaluating monotherapies and combinations, is enrolling ahead of schedule and has an increased enrollment target, with induction data expected in the third quarter of 2027.
The rheumatology program produced a clear negative portfolio decision. SPY072 showed statistically significant benefits on one or more endpoints in the RA sub-study, but the company said the magnitude of benefit did not meet its internal bar for prioritization. In PsA and axSpA, SPY072 was well tolerated but neither sub-study met its primary endpoint. Spyre therefore does not plan to advance SPY072 in rheumatic diseases, while repositioning the asset for HS as monotherapy and in combination with IL-17A/F inhibition.
The income statement reflects increased development activity. Third-quarter R&D expenses were $89.2 million versus $45.2 million in the prior-year quarter, driven primarily by manufacturing costs and clinical trial expenses. G&A expenses were $16.6 million versus $11.6 million. Net loss was $96.1 million, compared with $11.2 million, while other income declined to $9.6 million from $45.7 million because the prior period included changes in the fair value of the CVR liability.
Liquidity was materially reinforced after quarter end. Spyre reported $1,071.9 million of cash, cash equivalents, and marketable securities as of September 30, 2026, and pro forma cash of $1,467.9 million after reflecting $378.0 million of net offering proceeds and $18.0 million of ATM sales in October. The company expects this capital to fund operations into the second half of 2029. The next major operating milestones are SKYLINE combination induction data in the third quarter of 2027 and SKYLIGHT Week 16 data in late 2027 or early 2028.
Management, verbatim
We are increasingly well-positioned to deliver on our ambition of elevating the standard of care across immunology. In IBD, our three compelling Phase 2 monotherapy readouts and a growing body of supportive clinical evidence strengthen our conviction that our combination products have the potential to transform the treatment paradigm.
Cameron Turtle, DPhil, Chief Executive Officer of Spyre
The combination portion of our SKYLINE trial is enrolling faster than expected enabling an increased enrollment target, and we plan to deliver topline data in Q3 2027 with the potential for efficacy, safety, and convenience that meaningfully surpasses today's standard of care.
Cameron Turtle, DPhil, Chief Executive Officer of Spyre
Not in the filing
stated, not guessed- Total revenue was not reported.
- Revenue by segment was not reported.
- Gross profit and gross margin were not reported.
- Non-GAAP financial measures, including non-GAAP operating income and non-GAAP EPS, were not reported.
- Free cash flow was not reported.
- Debt balances were not reported.
- Share repurchases and dividends were not reported.
- Formal revenue, gross-margin, operating-expense, or tax-rate guidance was not reported.
- Prior-quarter comparisons for the reported operating results were not reported.
- Nothing comparable: the prior outlook is for milestones and cash runway, and the release reports only Q3 financial results with no matching guided metric.
Written by an AI language model from the company’s SEC earnings filing (Form 8-K Item 2.02, or Form 6-K for a foreign private issuer). Every figure is checked against the filing text, and a metric the filing does not print, or whose value, prior period and change do not add up, is dropped from the metrics. Guided figures in the outlook comparison come from the company’s previous release. The model can still misread a table, in the metrics or in the text, so check a number in the filing before you rely on it. Consensus estimates, price targets and share-price reactions are not shown because they are not in the filing. AI-generated research, not investment advice.